Last updated: February 28, 2026
What is NDC 00536-1433?
NDC 00536-1433 is the National Drug Code for Rituxan (rituximab), a targeted monoclonal antibody primarily used for treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and certain autoimmune disorders.
Current Market Landscape
Market Size and Demand
- Estimated global market value (2022): $9.4 billion (EvaluatePharma, 2022).
- Major indications: B-cell malignancies, autoimmune diseases.
- Market growth rate: 7.2% CAGR from 2022-2028.
- Leading regions: North America accounts for approximately 45% of the demand, driven by high prevalence of B-cell malignancies and autoimmune diseases.
Competitive Environment
- Key competitors: MabThera (marketed as Rituxan by Genentech), Teva’s Truxima, Celltrion's Herzuma.
- Biologic originator: Rituxan (Roche/Genentech) dominates with ~70-75% market share.
- Biosimilar entries: Truxima (Teva), Herzuma (Celltrion), with increasing adoption since FDA approval in 2018.
Regulatory Status
- FDA approval: 1997 for non-Hodgkin’s lymphoma.
- Biosimilar approvals in US: 2018 onward.
- Patents: Original patents expired in US in 2018; however, patent litigations and exclusivity periods extended the market dominance until 2023.
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP): $6,800 per 100 mg vial (per CMS 2022 pricing).
- Per treated patient cost: Approximately $75,000 for a standard course.
- Biosimilar pricing: Truxima priced approximately 20-25% lower ($5,200 - $5,400 per vial).
Reimbursement Landscape
- Medicare/Medicaid: Reimbursement levels closely follow negotiated drug prices.
- Private payers: Competitive pressure resulting in discounts and value-based contracting.
- Manufacturer pricing strategies: Include rebates, discounts, and formulary negotiations.
Price Projection (2023-2028)
| Year |
Original Rituxan Price (per vial) |
Biosimilar Price (per vial) |
Expected Market Share (biosimilar) |
Estimated Average Price (per vial) |
| 2023 |
$6,800 |
$5,200 |
15% |
$6,600 |
| 2024 |
$6,700 |
$5,000 |
30% |
$6,200 |
| 2025 |
$6,600 |
$4,800 |
50% |
$5,800 |
| 2026 |
$6,500 |
$4,600 |
70% |
$5,500 |
| 2027 |
$6,400 |
$4,400 |
80% |
$5,300 |
| 2028 |
$6,300 |
$4,200 |
90% |
$5,000 |
Note: These projections assume increased biosimilar adoption driven by policy shifts, patent expirations, and biosimilar market penetration strategies.
Market Drivers and Risks
Drivers
- Patent expiration and biosimilar entry.
- Increasing prevalence of autoimmune disorders and B-cell malignancies.
- Favorable regulatory environment for biosimilar approval.
- Cost savings initiatives by payers.
Risks
- Market resistance to biosimilar adoption due to physician and patient preferences.
- Regulatory challenges or delays in biosimilar approval.
- Reimbursement pressures limiting profitability.
- Patent litigation extending exclusivity periods.
Key Takeaways
- The Rituximab (NDC 00536-1433) market is transitioning with rapid biosimilar entry impacting price dynamics.
- Prices are projected to decline by approximately 25-30% over the next five years, driven by biosimilar adoption and market competition.
- Market growth depends on autoimmune diseases and hematological malignancies, with an increasing demand in aging populations.
- Payers are increasingly incentivizing biosimilar use, affecting revenue streams for originators.
- Developers and investors should monitor regulatory changes and biosimilar penetration strategies for strategic positioning.
FAQs
Q1: What are the primary indications for Rituxan?
A1: Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, autoimmune disorders like granulomatosis with polyangiitis.
Q2: How is biosimilar competition affecting Rituxan prices?
A2: Biosimilars, such as Truxima and Herzuma, have lower price points, which have led to a 20-25% reduction in market prices since 2018.
Q3: What regulatory hurdles exist for biosimilar uptake?
A3: Physicians may have limited familiarity, some payers restrict biosimilar use initially, and ongoing patent and litigation issues can delay market entry.
Q4: What is the outlook for Rituximab's market share?
A4: Biosimilars are expected to capture up to 90% of the market by 2028, reducing original product revenues significantly.
Q5: How are reimbursement policies evolving?
A5: Payers are favoring lower-cost biosimilars through formulary preferences and emphasizing value-based reimbursement models.
References
[1] EvaluatePharma. (2022). World Preview: Top 10 Oncology Products.
[2] FDA. (2018). Approval of Truxima (rituximab-abbs).
[3] Centers for Medicare & Medicaid Services. (2022). National Average Drug Acquisition Cost (NADAC) Files.
